Cellceutix has brought together leading figures in the health and science arenas to work toward the goal of developing innovative small molecule therapies for areas of unmet medical need, particularly cancer and inflammatory disease. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as people with wide experience in the pharmaceutical business and their invaluable experiences cover all areas of researching, developing, and marketing ground breaking therapies.
 |
Chief Executive Officer, Chairman of the Board of Directors- George W. Evans, JD, MBA;
George Evans has more than 25 years experience in the Pharmaceutical industry. He worked in a number of positions for Pfizer Inc, ending his career there as General Counsel for Pfizer's worldwide prescription drug unit, and a member of the unit's leadership team. During his time at Pfizer Mr. Evans gained experience in all aspects of the pharmaceutical business, from early stage research to end-of-life-cycle strategies. Mr. Evans also played a key part in negotiating several major transactions for Pfizer. In addition to his direct business experience, Mr. Evans has a wealth of experience in building and integrating organizations while maintaining the highest levels of performance. Mr. Evans was a member of the Editorial Advisory Board and the Finance Committee of the Food and Drug Law Institute and a member of the Board of the City Bar Fund. He is a graduate of Williams College and Columbia University's Law and Business schools.
|
 |
President, Chief Scientific Officer, Board of Directors - Dr. Krishna Menon
RCM, PhD, VMD - Dr. Krishna Menon has more than 35 years in drug development for academia and industry. Originally trained as a veterinary surgeon, Menon began his career as Chief Government Veterinarian for a major Parish in Jamaica. He segued to a three-year stint as Director of Agriculture for the Cayman Islands, in the British Caribbean and, in 1982, moved to the Dana Farber Cancer Research Institute, where he worked under the direction of Dr. Emil Frei. Two years later, he earned his PhD in Pharmacology from Harvard University. Menon's PhD work focused on anti-folate therapy of various cancers. Menon was a Research Scientist at Dana Farber from 1985 to 1990 and Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) from 1991 to 1993. After a year operating his own veterinary oncology and drug development consultancy practice, Menon was tapped Group Leader, Cancer In Vivo Research and Clinical Development, for Eli Lilly (1995-2001), where he played a key role in lead selection and pre-clinical development of Gemzar and Alimta which in 2006 had over 2.1 billion dollars ($2,100,000,000) in sales, and is a co-developer of another seven compounds currently in late-stage clinical development. In 1999, Lilly honored Menon with the President's Recognition Award, an award not bestowed annually but rather on only special occasions.
|
 |
Chief Financial Officer, Board of Directors- Leo Ehrlich, CPA
Served as Chief Financial Officer (CFO) of Cellceutix Pharma since inception in June 2007. Following the acquisition, he was appointed CFO and a director. From October 8, 1999 to the present time, Mr. Ehrlich has been a director at StatSure Diagnostic Systems, Inc. and has held different executive officer positions at that company including CEO, President, and his current title of CFO. Mr. Ehrlich was also CFO and a director of Nanoviricides, Inc. from June 1, 2005. until May 2007. Mr. Ehrlich is a Certified Public Accountant and received his BBA from Bernard Baruch College of the City University of New York.
|
 |
Emil Frei III, MD
Dr. Frei is one of the world's leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education. His distinguished career includes 40 years in top leadership positions such as Chief of Medicine at National Cancer Institute, Associate Scientific Director at M. D. Anderson, and Director and Physician-in-Chief at the Dana-Farber Cancer Institute. He continues as Physician-in-Chief, Emeritus, at Dana-Farber.
|
 | Dr. Samuel Danishefsky, Scientific Advisor
Dr. Samuel Danishefsky is an internationally recognized leader in chemistry, specializing in the synthesis of biologically active organic compounds. He is regarded as one of the world's leading chemists in cancer research. Dr. Danishefsky earned his Ph.D. in chemistry from Harvard. He spent 14 years at Yale University, where he rose to the rank of Sterling Professor of Chemistry, the highest academic rank at Yale University, awarded to a tenured faculty member considered one of the best in his or her field. By 1991, he was also sharing his time with Memorial Sloan-Kettering Cancer Center as director of the Laboratory for Cancer Research Bioorganic Chemistry, becoming chair in 1993. He accepted an appointment as professor at Columbia University in 1993, and now conducts research at both institutions. Further information is available at www.mskcc.org/mskcc/html/64932.cfm
AWARDS
- Shared the distinguished Wolf Award and $100,000 Prize, with Gilbert Stork
- American Chemical Society's Guenther Award
- Aldrich Award for Creative Work in Synthetic Organic Chemistry
- Benjamin Franklin Medal in Chemistry
- National Academy of Sciences' NAS Award in Chemical Sciences
- Cope Medal -- American Chemical Society
- And numerous other awards.
|
|
Home 
Sitemap
Contact Us
